Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 7, 2020
Principal Executive Offices: Stoughton, MA
Trading Symbol: COLL (NASDAQ Global Select Market)
Emerging Growth Company: Yes
Key Financial Metrics
This filing does not contain historical financial statements, revenue, profit, cash flow, or debt figures. The report serves to disclose forward-looking guidance issued via a press release (Exhibit 99.1). Specific numerical values for 2020 revenue and operating expenses are referenced as being contained in the attached press release but are not explicitly detailed in the text of this 8-K filing.
Material Changes
No historical material changes are reported in this document. The filing announces the issuance of full-year 2020 guidance for:
- Xtampza ER revenues
- Nucynta Franchise revenues
- Total operating expenses
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on January 7, 2020, providing full-year 2020 guidance. These statements are forward-looking and reflect current management beliefs.
Key Risks and Uncertainties: The filing highlights substantial risks that could cause actual results to differ from guidance, including:
- Regulatory approval maintenance and label restrictions.
- Commercialization success and market acceptance of products.
- Reimbursement and third-party payor contract status.
- Competition from other products.
- Intellectual property litigation, specifically with Purdue Pharma, L.P. and Teva Pharmaceuticals USA, Inc.
- Supply chain reliability for active pharmaceutical ingredients.
- Compliance with DEA and other government regulations.
- Loss of key personnel.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific 2020 revenue and expense guidance numbers.
- Monitor the status of litigation with Purdue Pharma and Teva Pharmaceuticals.
- Verify regulatory standing and label warnings for Xtampza ER and Nucynta.
- Assess the Company's ability to secure reimbursement contracts for its product franchise.
- Check supply chain stability for active pharmaceutical ingredients.